References
- Urba W. J., Longo D. L. Hodgkin's disease. N. Engl. J. Med. 1992; 326, (10), 678–687
- Reece D. E., Barnett M. J., Connors J. M., Fairey R. N., Fay J. W., Greer J. P., Herzig G. P., Herzig R. H. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J. Clin. Oncol. 1991; 9, (10), 1871–1879
- Jones R. J., Piantadosi S., Mann R. B., Ambinder R. F., Seifter E. J., Vriesendorp H. M., Abeloff M. D., Burns W. H., May W. S., Rowley S. D. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J. Clin. Oncol. 1990; 8, (3), 527–537
- Chopra R., McMillan A. K., Linch D. C., Yuklea S., Taghipour G., Pearce R., Patterson K. G., Goldstone A. H. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993; 81, (5), 1137–1145
- Vose J. M., Bierman P. J., Anderson J. R., Kessinger A., Pierson J., Nelson J., Frappier B., Schmit-Pokorny K., Weisenburger D. D., Armitage J. O. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80, (8), 2142–2148
- Lee E. T. Statistical methods for survival data analysis, 2nd ed. Wiley & Sons, New York 1992; 66–78
- Statistical Analysis System (SAS) STAT User's Guide, Version 6, 4th Ed., Volume 2. SAS Institute, Inc, Cary, NC 1990; 1027–1070
- Kalbfleisch J. D., Prentice R. L. The statistical analysis of failure time data. John Wiley & Sons, New York 1980
- Ratanatharathorn V., Karanes C., Lum L. G., Uberti J., Dan M. E., De Planque M. M., Schultz K. R. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC). Bone Marrow Transplant. 1992; 9: 49–55
- Ratanatharathorn V., Uberti J., Karanes C., Lum L. G., Abella E., Dan M. E., Hussein M., Sensenbrenner L. L. Phase I study of alpha-interferon augmentation of cyclosporine-induced graft versus host disease in recipients of autologous bone marrow transplantation. Bone Marrow Transplant. 1994; 13: 625–630
- Goldstone A. H., Linch D. C., Gribben J. C. European experience of autologous bone marrow transplantation in lymphoma. J. Cell Biochem. 1988; 79
- Krikorian J. G., Burke J. S., Rosenberg S. A., Kaplan H. S. Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. N. Engl. J. Med. 1979; 300, (9), 452–8
- Zarrabi M. H., Rosner F. Second neoplasms in Hodgkin's disease: current controversies. Hematology/Oncology Clinics of North America 1989; 3, (2), 303-
- Mrsic M., Horowitz M., Atkinson K. Second HLA-identical sibling transplant for leukemia recurrence. Bone Marrow Transplant. 1992; 9: 269–276
- Avalos B. R., Copelan E. A. Second autologous bone marrow transplantation in Hodgkin's disease. Bone Marrow Transplant. 1993; 12: 665–667
- Miller J. S., Arthur D. C., Litz C. E., Neglia J. P., Miller W. J., Weisdorf D. J. Myelodysplastic syndrom after autologous bone marrow tranplantation: an additional late complication of curative cancer therapy. Blood 1994; 83, (12), 3780–3786